Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Natura:	Journal article
Lingua:	English
Pubblicazione:	MDPI 2021

Documenti analoghi

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
di: Michael Riste, et al.
Pubblicazione: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
di: Thomas, Z, et al.
Pubblicazione: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
di: Tameris, M, et al.
Pubblicazione: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
di: Tameris, M, et al.
Pubblicazione: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
di: Mcshane, H
Pubblicazione: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
di: Manjaly Thomas, Z, et al.
Pubblicazione: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
di: Rowland, R, et al.
Pubblicazione: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
di: Michele Tameris, et al.
Pubblicazione: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
di: Harris, S, et al.
Pubblicazione: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
di: Meyer, J, et al.
Pubblicazione: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
di: Meyer, J, et al.
Pubblicazione: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
di: Zita-Rose Manjaly Thomas, et al.
Pubblicazione: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
di: Anne Wajja, et al.
Pubblicazione: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
di: Wajja, A, et al.
Pubblicazione: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
di: Sander, C, et al.
Pubblicazione: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
di: Minassian, A, et al.
Pubblicazione: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
di: Harris, S, et al.
Pubblicazione: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
di: Odutola, A, et al.
Pubblicazione: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
di: Odutola, A, et al.
Pubblicazione: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
di: Dieye, T, et al.
Pubblicazione: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
di: Wilkie, M, et al.
Pubblicazione: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
di: Whelan, K, et al.
Pubblicazione: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
di: Pathan, A, et al.
Pubblicazione: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
di: Pathan, A, et al.
Pubblicazione: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
di: Owiafe, P, et al.
Pubblicazione: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
di: Tandakha N Dieye, et al.
Pubblicazione: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
di: Kathryn T. Whelan, et al.
Pubblicazione: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
di: Wilkie, M, et al.
Pubblicazione: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
di: Tandakha N. Dieye, et al.
Pubblicazione: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
di: Minhinnick, A, et al.
Pubblicazione: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
di: C.N. Govind, et al.
Pubblicazione: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
di: F. Ismail, et al.
Pubblicazione: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Pubblicazione: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
di: Raksha Rimal, et al.
Pubblicazione: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
di: Giovana Rodrigues Pereira, et al.
Pubblicazione: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
di: Neeraj Raizada, et al.
Pubblicazione: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
di: Mcshane, H, et al.
Pubblicazione: (2016)

TB or not TB?
di: Andrew Pirotte, et al.
Pubblicazione: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
di: Satti, I, et al.
Pubblicazione: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
di: Satti, I, et al.
Pubblicazione: (2014)